Life-prolonging treatments for end-stage demented patients are costly and of questionable value. Because most elderly individuals have not made directives in advance, decisions concerning their health care are made by surrogates, usually close family members. Currently, there are no standard methods for educating these surrogates concerning health care options and assisting them in decision making. The Pilot will determine the impacts of a structured intervention with families, focusing on the decision-making process of surrogates, distress to caregivers/families, and several outcome measures (e.g., clinical course, survival, and use of health care resources). The sample consists of 97 patients of Cohort 1 with severe Alzheimer's disease (AD), who have been followed in our Alzheimer's Disease Research Center (ADRC) for the past ten years, and their caregivers. The neurological, cognitive, physical, and functional status of patients will be documented, and we will analyze the effects, over the previous six months, of five activities: hospitalization; use of antibiotics; artificial feeding and hydration; resuscitation; and the use of diagnostic tests. The impacts of interventions on the emotional health and decisions of caregivers will be elicited through the use of mailed questionnaires. Caregivers will be assigned randomly to an educational group or a control group. The forum of the educational group will be two sessions of counselling concerning the rationale for specific interventions; control caregivers will not participate in this process. Six months later, we will assess the efficacies of the sessions on several parameters that focus on decision making in health care and benefits/feedback for surrogates, caregivers, and patients. We believe the study of this relatively neglected area may help us to design more effective strategies for dealing with issues commonly encountered in this population of elderly individuals.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005146-13
Application #
3726324
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
13
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
045911138
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Fredericks, Carolyn A; Sturm, Virginia E; Brown, Jesse A et al. (2018) Early affective changes and increased connectivity in preclinical Alzheimer's disease. Alzheimers Dement (Amst) 10:471-479
Seddighi, Sahba; Varma, Vijay R; An, Yang et al. (2018) SPARCL1 Accelerates Symptom Onset in Alzheimer's Disease and Influences Brain Structure and Function During Aging. J Alzheimers Dis 61:401-414
Alosco, Michael L; Sugarman, Michael A; Besser, Lilah M et al. (2018) A Clinicopathological Investigation of White Matter Hyperintensities and Alzheimer's Disease Neuropathology. J Alzheimers Dis 63:1347-1360
Holingue, Calliope; Wennberg, Alexandra; Berger, Slava et al. (2018) Disturbed sleep and diabetes: A potential nexus of dementia risk. Metabolism 84:85-93
Brent, Robert J (2018) Estimating the monetary benefits of medicare eligibility for reducing the symptoms of dementia. Appl Econ 50:6327-6340
van Bergen, Jiri M G; Li, Xu; Quevenco, Frances C et al. (2018) Low cortical iron and high entorhinal cortex volume promote cognitive functioning in the oldest-old. Neurobiol Aging 64:68-75
Deming, Yuetiva; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-specific genetic predictors of Alzheimer's disease biomarkers. Acta Neuropathol 136:857-872
Kim, Sangjune; Yun, Seung Pil; Lee, Saebom et al. (2018) GBA1 deficiency negatively affects physiological ?-synuclein tetramers and related multimers. Proc Natl Acad Sci U S A 115:798-803
Hohman, Timothy J; Dumitrescu, Logan; Barnes, Lisa L et al. (2018) Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. JAMA Neurol 75:989-998
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211

Showing the most recent 10 out of 830 publications